5 Ankylosing Spondylitis Clinical Trials in Pasadena, TX (2026)

Q: How do I join a clinical trial in Pasadena?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Pasadena research site will contact you.

Recruiting Ankylosing Spondylitis Studies in Pasadena

NCT06937229Recruiting

A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)

The purpose of this study is to evaluate the long-term efficacy and safety of combined formulation of xanomeline tartrate/trospium chloride in an immediate release (IR) capsule (KarXT) and xanomeline ...

Pasadena, TX650 participantsBristol-Myers Squibb

View Study Details

NCT07011745Recruiting

A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-2)

The purpose of this study is to evaluate the efficacy and safety of KarXT + KarX-EC in adult participants with agitation related to Alzheimer's Disease....

Pasadena, TX352 participantsBristol-Myers Squibb

View Study Details

NCT07527910Recruiting

A Phase 2a Study of ALN-PNP With and Without a GLP1R Agonist in Adult Patients With Homozygous PNPLA3-Related MASLD

This study will test a study drug called ALN-PNP with and without another drug that is used for controlling blood sugar, appetite, and weight (for example, tirzepatide), to see if it can help treat MA...

Pasadena, TX204 participantsRegeneron Pharmaceuticals

View Study Details

NCT07009860Recruiting

RESTORE TRIAL: A Phase 2 Study Evaluating the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol-Associated Liver Disease (ALD)

This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of pemvidutide in subjects with ALD. * Pemvidutide: 2.4 mg SC once weekly * Plac...

Pasadena, TX100 participantsAltimmune, Inc.

View Study Details

NCT07017673Recruiting

Phase II Trial of Ivonescimab in Combination With Carboplatin + Docetaxel in Patients With Early-Stage Triple Negative Breast Cancer

This is a single arm phase II trial combination of ivonescimab and carbo-docetaxel every 3 weeks for 6 cycles in patients with early-stage triple negative breast cancer. The trial is designed to test ...

Pasadena, TX34 participantsCedars-Sinai Medical Center

View Study Details

About Ankylosing Spondylitis Clinical Trials in Pasadena

Ankylosing spondylitis is a chronic inflammatory disease primarily affecting the spine and sacroiliac joints, causing pain, stiffness, and potentially spinal fusion. It typically begins in early adulthood. Treatment includes NSAIDs, biologics (TNF and IL-17 inhibitors), and physical therapy.

There are currently 5 ankylosing spondylitis clinical trials recruiting participants in Pasadena, TX. These studies are seeking a combined 1,340 participants. Research is being sponsored by Bristol-Myers Squibb, Regeneron Pharmaceuticals, Altimmune, Inc. and 1 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Ankylosing Spondylitis Clinical Trials in Pasadena — FAQ

Are there ankylosing spondylitis clinical trials in Pasadena?

Yes, there are 5 ankylosing spondylitis clinical trials currently recruiting in Pasadena, TX. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Pasadena?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Pasadena research site will contact you about next steps.

Are clinical trials in Pasadena free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Pasadena studies also compensate for your time and travel.

What ankylosing spondylitis treatments are being tested?

The 5 active trials in Pasadena are testing new therapies including novel drugs, biologics, and treatment approaches for ankylosing spondylitis.

Data updated July 13, 2026 from ClinicalTrials.gov